{
    "clinical_study": {
        "@rank": "151485", 
        "acronym": "PRO-IMPACT", 
        "arm_group": [
            {
                "arm_group_label": "Salvage setting", 
                "arm_group_type": "Other", 
                "description": "The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)"
            }, 
            {
                "arm_group_label": "Adjuvant setting", 
                "arm_group_type": "Other", 
                "description": "The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)"
            }
        ], 
        "brief_summary": {
            "textblock": "To determine the extent to which use of the Decipher test influences urologist and patient\n      treatment plan choices immediately post RP and at the time of PSA rise or BCR"
        }, 
        "brief_title": "Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This prospectively decision impact study will evaluate physicians and patient treatment plan\n      choices before and after reviewing Decipher results for eligible patient cases. The clinical\n      utility of Decipher will be evaluated for patients meeting the inclusion criteria at two\n      time-points post-RP:\n\n        1. In the adjuvant setting: within 12 months after surgery (in the absence of detectable\n           PSA rise of BCR)\n\n        2. In the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA\n           detectable and rising on 2 or more subsequent determinations)\n\n      A total of 150 patient cases, in each arm, will be prospectively selected from clinical\n      sites. The study as a whole will enroll 300 patient cases.\n\n      As a condition of participation in the study, each clinical site must agree to provide a\n      minimum of 10 patient cases."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Pathological T3 stage of disease (i.e., EPE or SVI), or\n\n          2. Positive surgical margins, or\n\n          3. Detectable PSA, defined as PSA detectable and rising on 2 or more subsequent\n             determinations\n\n        Exclusion Criteria:\n\n          1. For adjuvant setting patients: Metastatic Disease (M+) prior to surgery\n\n          2. For salvage setting patients: Metastatic Disease at PSA rise\n\n          3. Failure of PSA to nadir after surgery\n\n          4. Received any neo-adjuvant prostate cancer treatment before radical prostatectomy\n\n          5. Received any adjuvant chemotherapy\n\n          6. Required patient clinical data is not available for evaluation of eligibility\n             criteria\n\n          7. For adjuvant setting patients, any treatment received after surgery\n\n          8. For salvage setting patients, lack of documented treatment or management\n             recommendation on file\n\n          9. Tissue specimen is inadequate for sampling and analysis"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080689", 
            "org_study_id": "CU 004"
        }, 
        "intervention": {
            "arm_group_label": [
                "Salvage setting", 
                "Adjuvant setting"
            ], 
            "intervention_name": "Decipher", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 5, 2014", 
        "link": {
            "description": "The Society of Urologic Oncology (SUO)", 
            "url": "http://suonet.org/default.aspx"
        }, 
        "location": {
            "contact": {
                "email": "clinops@genomedx.com", 
                "last_name": "Christine Buerki, PhD", 
                "phone": "888-975-4540"
            }, 
            "contact_backup": {
                "email": "clinops@genomedx.com", 
                "last_name": "Marguerite du Plessis", 
                "phone": "1-888-975-4540"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington"
                }, 
                "name": "University of Washington"
            }, 
            "investigator": {
                "last_name": "Daniel W Lin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "PROspective Study of the IMPACT of Decipher\u2122 Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]", 
        "overall_contact": {
            "email": "christine@genomedx.com", 
            "last_name": "Christine Buerki, PhD", 
            "phone": "1-888-975-4540"
        }, 
        "overall_official": {
            "affiliation": "The Society of Urologic Oncology (SUO)", 
            "last_name": "Daniel W Lin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants for which the Decipher test changes the urologist's and patient's treatment plan choices", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "reference": [
            {
                "PMID": "21402604", 
                "citation": "Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011 Apr 20;29(12):1517-24. doi: 10.1200/JCO.2010.31.1217. Epub 2011 Mar 14."
            }, 
            {
                "PMID": "21197260", 
                "citation": "Swanson GP, Basler JW. Prognostic factors for failure after prostatectomy. J Cancer. 2010 Dec 7;2:1-19."
            }, 
            {
                "PMID": "21484780", 
                "citation": "Silberstein JL, Vickers AJ, Power NE, Fine SW, Scardino PT, Eastham JA, Laudone VP. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer. 2011 Nov 1;117(21):4855-60. doi: 10.1002/cncr.26132. Epub 2011 Apr 11."
            }, 
            {
                "PMID": "19167731", 
                "citation": "Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar;181(3):956-62. doi: 10.1016/j.juro.2008.11.032. Epub 2009 Jan 23."
            }, 
            {
                "PMID": "23084481", 
                "citation": "Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012 Dec 8;380(9858):2018-27. doi: 10.1016/S0140-6736(12)61253-7. Epub 2012 Oct 19."
            }, 
            {
                "PMID": "19433689", 
                "citation": "Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, St\u00f6rkel S, Willich N, Semjonow A, Souchon R, St\u00f6ckle M, R\u00fcbe C, Weissbach L, Althaus P, Rebmann U, K\u00e4lble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009 Jun 20;27(18):2924-30. doi: 10.1200/JCO.2008.18.9563. Epub 2009 May 11."
            }, 
            {
                "PMID": "20159826", 
                "citation": "Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010 Mar 20;28(9):1508-13. doi: 10.1200/JCO.2009.22.2265. Epub 2010 Feb 16."
            }, 
            {
                "PMID": "17105795", 
                "citation": "Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15;296(19):2329-35."
            }, 
            {
                "PMID": "21074194", 
                "citation": "Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol. 2011 Jan;185(1):116-20. doi: 10.1016/j.juro.2010.08.086. Epub 2010 Nov 12."
            }, 
            {
                "PMID": "18165645", 
                "citation": "Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol. 2008 Jan 1;26(1):112-20. doi: 10.1200/JCO.2006.10.4505."
            }, 
            {
                "PMID": "23826159", 
                "citation": "Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013."
            }, 
            {
                "PMID": "23770138", 
                "citation": "Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11."
            }, 
            {
                "PMID": "23592338", 
                "citation": "Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 2013 Apr;4(4):600-9."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This outcome will compare recommended treatment pre-Decipher to recommended treatment post-Decipher", 
                "measure": "Measure the number of participants for which treatment was Increased or decreased in the intensity.", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "The number of different treatment plans most influenced by Decipher as a measure of clinical utility", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "How many treatment plans are similar for those considered at high versus low risk by Decipher test", 
                "measure": "Comparison of  type of treatment plans between high risk and low risk patients", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Account for the number of specific treatment assignments that correlated with a change in treatment recommendation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The extent to which the Decipher test results influence urologist recommendations on frequency of follow-up for patients", 
                "measure": "Frequency of follow visits as a measure of reproducibility", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Measure the urologist's and patient's Level of confidence in their selected treatment plan through the use of a share decision making tool", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "measure": "Assess the number of physicians that assigned the same treatment treatment recommendations for patient of the same pathological profile as a measure of concordance", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The extent to which the Decipher test results affect patient comfort level with treatment decisions as based on QOL and treatment regret tools", 
                "measure": "A measure of the patient's quality of life (QOL) as a measure of Decipher's clinical utility for patients", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "For how many cases was the original selected treatment for a patient actually executed upon", 
                "measure": "Evaluate number of participants which show coherence to treatment decisions", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "GenomeDx Biosciences Corp", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GenomeDx Biosciences Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}